News · Oruka Therapeutics, Inc. (ORKA) · Healthcare

Oruka Therapeutics rises after positive Phase IIb psoriasis data

Session of October 26, 2026 · Published October 27, 2026 · 4 min read

What happened

Oruka Therapeutics (ORKA) rose 12.7% on October 26, 2026, after it reported interim week-16 results from the EVERLAST-B Phase IIb study showing the 600-mg regimen produced PASI 100 in 61% of participants and PASI 90 in 86% at week 16. GlobeNewsWire and Benzinga reported that the company said safety and tolerability were favorable and consistent with the IL-23p19 class. Oruka said ORKA-001 is expected to move into Phase 3 testing in the first half of 2027 and flagged additional milestones, including 52-week EVERLAST-A results expected in December 2026 and ORKA-002 ORCA-SURGE 16-week results on track for 1Q 2027.

Closing price over the last 30 trading sessions. On October 26, 2026, ORKA closed at $90.33, up 12.7% on the day and 2.0% lower than 30 sessions earlier.

How big was the move

The stock closed at $90.33, a rise of 12.7% for the session, and it rose 21.3% over the last five sessions. Trading volume was 2.1 times its 20-day average, and the session’s move measured 3.9 times a typical daily move for this stock. The S&P 500 rose 0.7% on the day while the Healthcare sector median fell 0.1%, leaving the stock 12.8 percentage points better than the sector median. In the past five years the stock had eight sessions with a gain of at least 12.7%; twenty trading days later the median result was a gain of 9.3% and six of eight were higher.

Each bar is one day's price change; the outlined bar is October 26, 2026. A typical daily move over the past year was 4.3%, so the latest move equals 3.0 times that. Moves outside the dashed lines (about 8.5%) are unusual.

The size and timing point to company-specific news as the likely driver: the interim trial data came the same day the stock jumped, and the move was far larger than the market and its sector.

The technical picture

The stock sat 12.7% above its 20-day moving average and 0.8% above its 50-day moving average, while it traded 33.0% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock had spent 303 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) read 61, in a neutral range between 30 and 70, and the stock was 21.8% below its 52-week high.

Closing price over the past year. ORKA ends the period 20.1% below its 52-week high, above its 50-day average ($89.57) and above its 200-day average ($67.92).

Recent price action showed mixed intermediate performance: the stock rose 7.0% over one month, fell 0.1% over three months and rose 233.0% over one year, which is 219.0 percentage points ahead of the S&P 500. Volatility was 52% annualized over 60 days, lower than 51% of its own readings over five years, and the stock’s beta of 0.88 indicates it tends to move less than the broader market.

Fundamentals and valuation

For the four quarters through June 30, 2026, the company reported revenue of $0 and diluted earnings per share of $-2.47. The balance sheet showed net cash of $265.9 million, while return on invested capital registered 13.9%. Share count over one year increased by 48.9% and free-cash-flow yield stood at 1.9%.

Quarterly revenue by period end. The latest quarter brought $0.00.

Those figures underscore Oruka’s clinical-stage profile: it has no product revenue but holds meaningful cash to fund programs through nearer-term milestones. The large rise in shares outstanding reflects financing or equity compensation typical for a company advancing trials, and the modest free-cash-flow yield highlights limited current cash generation.

PromtFinance scores situate the stock high on Momentum at 91 (Exceptional) but weaker on Quality at 32 (Weak), with Value at 62 (Neutral), Revisions at 63 (Neutral) and Stability at 49 (Neutral). The contrast between strong momentum and weaker quality measures captures the market’s enthusiasm for positive trial data even as the company remains pre-revenue.

Earnings and analyst expectations

Oruka’s next quarterly report is scheduled for November 11, 2026. The last report, on August 10, 2026, showed earnings per share of $-0.55 against $-0.51 expected, 7.3% below estimates, and the company has zero consecutive quarters beating estimates. Average surprise over the last four reports was 8.2% above estimates, and a typical two-day reaction after recent reports was that the stock fell 0.8%.

Diluted earnings per share by quarter. The latest quarter shows -$0.66, against -$0.58 in the same quarter a year earlier.

Nine analysts cover the stock and the consensus rating is Buy; 100% of the analysts rate the stock Buy or Strong Buy. Their consensus price target is $144.56, which is 60.0% above the closing price, reflecting optimism about the company’s clinical pathway and the potential commercial upside if late-stage trials and approvals succeed.

What to watch

November 11, 2026: next quarterly report date.
December 2026: 52-week EVERLAST-A results expected.
First half of 2027: ORKA-001 planned to move into Phase 3 testing.
1Q 2027: ORKA-002 ORCA-SURGE 16-week results on track.

Full ORKA analysis: scores, chart and financials →